publication . Article . 2021

Evaluating the impact of curfews and other measures on SARS-CoV-2 transmission in French Guiana

Andronico, Alessio; Tran Kiem, Cécile; Paireau, Juliette; Succo, Tiphanie; Bosetti, Paolo; Lefrancq, Noemie; Nacher, Mathieu; Djossou, Félix; Sanna, Alice; Flamand, Claude; ...
Open Access English
  • Published: 01 Dec 2021 Journal: Nature Communications, volume 12, issue 1, pages 1-8 (issn: 2041-1723, Copyright policy)
  • Publisher: Nature Publishing Group
Abstract
Funder: We acknowledge financial support from the Investissement d'Avenir program, the Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases program (Grant ANR-10-LABX-62-IBEID), Sante Publique France, the INCEPTION project (PIA/ANR-16-CONV-0005) and European Union V.E.O and RECOVER projects.
Subjects
free text keywords: Article, /631/114/2397, /631/114/2415, /631/326/596/4130, /692/700/478/174, /129, /141, [SDV]Life Sciences [q-bio], Article, /631/114/2397, /631/114/2415, /631/326/596/4130, /692/700/478/174, /129, /141, Computational models, Statistical methods, SARS-CoV-2, Epidemiology, General Biochemistry, Genetics and Molecular Biology, General Physics and Astronomy, General Chemistry, Humans, Hospitalization, Models, Statistical, Quarantine, Adolescent, Adult, Aged, Aged, 80 and over, Middle Aged, Child, Child, Preschool, Infant, Infant, Newborn, French Guiana, Female, Male, Basic Reproduction Number, Young Adult, Pandemics, COVID-19, SARS-CoV-2, Humans, Hospitalization, Models, Statistical, Quarantine, Adolescent, Adult, Aged, Aged, 80 and over, Middle Aged, Child, Child, Preschool, Infant, Infant, Newborn, French Guiana, Female, Male, Basic Reproduction Number, Young Adult, Pandemics, COVID-19, lcsh:Science, lcsh:Q
Related Organizations
Funded by
ANR| INCEPTION
Project
INCEPTION
Institut Convergences pour l’étude de l’Emergence des Pathologies au Travers des Individus et des populatiONs
  • Funder: French National Research Agency (ANR) (ANR)
  • Project Code: ANR-16-CONV-0005
Communities
COVID-19
27 references, page 1 of 2

1. ArcGIS Dashboards. Available at https://www.arcgis.com/apps/opsdashboard/ index.html#/bda7594740fd40299423467b48e9ecf6.

2. Salje, H. et al. Estimating the burden of SARS-CoV-2 in France. Science 369, 208-211 (2020). [OpenAIRE]

3. Flaxman, S. et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584, 257-261 (2020). [OpenAIRE]

4. Di Domenico, L., Pullano, G., Sabbatini, C. E., Boëlle, P.-Y. & Colizza, V. Impact of lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. BMC Med. 18, 1-13 (2020).

5. Roux J., Massonnaud C., Crépey P. COVID-19: One-month impact of the French lockdown on the epidemic burden. Preprint at https://www.medrxiv. org/content/10.1101/2020.04.22.20075705v1 (2020).

6. Mandel, A. & Veetil, V. The economic cost of COVID lockdowns: an out-ofequilibrium analysis. Econ. Disasters Clim. Change 4, 431-451 (2020).

7. Bonaccorsi, G. et al. Economic and social consequences of human mobility restrictions under COVID-19. Proc. Natl Acad. Sci. USA 117, 15530-15535 (2020).

8. Verity, R. et al. Estimates of the severity of coronavirus disease 2019: a modelbased analysis. Lancet Infect. Dis. 20, 669-677 (2020).

9. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054-1062 (2020).

10. Dowd, J. B. et al. Demographic science aids in understanding the spread and fatality rates of COVID-19. Proc. Natl Acad. Sci. USA 117, 9696-9698 (2020).

11. Tindale, L. C. et al. Evidence for transmission of COVID-19 prior to symptom onset. Elife 9, e57149 (2020).

12. Lefrancq N., et al. Evolution of outcomes for patients hospitalized during the first SARS-CoV-2 pandemic wave in France. Preprint at https://hal.archivesouvertes.fr/hal-02946545/document (2020).

13. Flamand C., et al. Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. Preprint at https://www.medrxiv.org/content/10.1101/ 2020.09.27.20202465v1 (2020).

14. Mellan T. A., et al. Subnational analysis of the COVID-19 epidemic in Brazil. Preprint at https://www.medrxiv.org/content/10.1101/2020.05.09.20096701v2 (2020).

15. COVID-19 epidemic in Brazil: where are we at? Int. J. Infect. Dis. 97, 382-385 (2020).

27 references, page 1 of 2
Abstract
Funder: We acknowledge financial support from the Investissement d'Avenir program, the Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases program (Grant ANR-10-LABX-62-IBEID), Sante Publique France, the INCEPTION project (PIA/ANR-16-CONV-0005) and European Union V.E.O and RECOVER projects.
Subjects
free text keywords: Article, /631/114/2397, /631/114/2415, /631/326/596/4130, /692/700/478/174, /129, /141, [SDV]Life Sciences [q-bio], Article, /631/114/2397, /631/114/2415, /631/326/596/4130, /692/700/478/174, /129, /141, Computational models, Statistical methods, SARS-CoV-2, Epidemiology, General Biochemistry, Genetics and Molecular Biology, General Physics and Astronomy, General Chemistry, Humans, Hospitalization, Models, Statistical, Quarantine, Adolescent, Adult, Aged, Aged, 80 and over, Middle Aged, Child, Child, Preschool, Infant, Infant, Newborn, French Guiana, Female, Male, Basic Reproduction Number, Young Adult, Pandemics, COVID-19, SARS-CoV-2, Humans, Hospitalization, Models, Statistical, Quarantine, Adolescent, Adult, Aged, Aged, 80 and over, Middle Aged, Child, Child, Preschool, Infant, Infant, Newborn, French Guiana, Female, Male, Basic Reproduction Number, Young Adult, Pandemics, COVID-19, lcsh:Science, lcsh:Q
Related Organizations
Funded by
ANR| INCEPTION
Project
INCEPTION
Institut Convergences pour l’étude de l’Emergence des Pathologies au Travers des Individus et des populatiONs
  • Funder: French National Research Agency (ANR) (ANR)
  • Project Code: ANR-16-CONV-0005
Communities
COVID-19
27 references, page 1 of 2

1. ArcGIS Dashboards. Available at https://www.arcgis.com/apps/opsdashboard/ index.html#/bda7594740fd40299423467b48e9ecf6.

2. Salje, H. et al. Estimating the burden of SARS-CoV-2 in France. Science 369, 208-211 (2020). [OpenAIRE]

3. Flaxman, S. et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584, 257-261 (2020). [OpenAIRE]

4. Di Domenico, L., Pullano, G., Sabbatini, C. E., Boëlle, P.-Y. & Colizza, V. Impact of lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. BMC Med. 18, 1-13 (2020).

5. Roux J., Massonnaud C., Crépey P. COVID-19: One-month impact of the French lockdown on the epidemic burden. Preprint at https://www.medrxiv. org/content/10.1101/2020.04.22.20075705v1 (2020).

6. Mandel, A. & Veetil, V. The economic cost of COVID lockdowns: an out-ofequilibrium analysis. Econ. Disasters Clim. Change 4, 431-451 (2020).

7. Bonaccorsi, G. et al. Economic and social consequences of human mobility restrictions under COVID-19. Proc. Natl Acad. Sci. USA 117, 15530-15535 (2020).

8. Verity, R. et al. Estimates of the severity of coronavirus disease 2019: a modelbased analysis. Lancet Infect. Dis. 20, 669-677 (2020).

9. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054-1062 (2020).

10. Dowd, J. B. et al. Demographic science aids in understanding the spread and fatality rates of COVID-19. Proc. Natl Acad. Sci. USA 117, 9696-9698 (2020).

11. Tindale, L. C. et al. Evidence for transmission of COVID-19 prior to symptom onset. Elife 9, e57149 (2020).

12. Lefrancq N., et al. Evolution of outcomes for patients hospitalized during the first SARS-CoV-2 pandemic wave in France. Preprint at https://hal.archivesouvertes.fr/hal-02946545/document (2020).

13. Flamand C., et al. Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. Preprint at https://www.medrxiv.org/content/10.1101/ 2020.09.27.20202465v1 (2020).

14. Mellan T. A., et al. Subnational analysis of the COVID-19 epidemic in Brazil. Preprint at https://www.medrxiv.org/content/10.1101/2020.05.09.20096701v2 (2020).

15. COVID-19 epidemic in Brazil: where are we at? Int. J. Infect. Dis. 97, 382-385 (2020).

27 references, page 1 of 2
Any information missing or wrong?Report an Issue